Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Sci Rep. 2023 Mar 20;13(1):4528. doi: 10.1038/s41598-023-31710-9.
Red ginseng has been used in traditional medicine for centuries in Asia. In this study, we evaluated four types of red ginseng grown in different areas (Chinese red ginseng, Korean red ginseng A, Korean red ginseng B, and Korean red ginseng C) for their ability to inhibit lung tumor formation and growth induced by the carcinogen benzo(a)pyrene (B(a)P) in A/J mice and found that Korean red ginseng B was the most effective at lowering the tumor load among the four red ginseng varieties. Moreover, we analyzed the levels of various ginsenosides (Rg1, Re, Rc, Rb2, Rb3, Rb1, Rh1, Rd, Rg3, Rh2, F1, Rk1, and Rg5) in four kinds of red ginseng extract and found that Korean red ginseng B had the highest level of ginsenoside Rg3 (G-Rg3), which suggested that G-Rg3 may play an important role in its therapeutic efficacy. This work revealed that the bioavailability of G-Rg3 was relatively poor. However, when G-Rg3 was coadministered with verapamil, a P-glycoprotein inhibitor, the G-Rg3 efflux in Caco-2 cells was lowered, the small intestinal absorption rate of G-Rg3 in the rat models was increased, the concentration levels of G-Rg3 were elevated in the intestine and plasma, and its tumor-preventive abilities in the tumorigenesis rat model induced by B(a)P were also augmented. We also found that G-Rg3 reduced B(a)P-induced cytotoxicity and DNA adduct formation in human lung cells and rescued phase II enzyme expression and activity through Nrf2 pathways, which may be the potential mechanisms underlying the inhibitory effects of G-Rg3 on lung tumorigenesis. Our study showed a potentially vital role of G-Rg3 in targeting lung tumors in murine models. The oral bioavailability of this ginsenoside was augmented by targeting P-glycoprotein, which allowed the molecule to exert its anticancer effects.
红参在亚洲传统医学中已经使用了几个世纪。在这项研究中,我们评估了在不同地区种植的四种红参(中国人参、韩国红参 A、韩国红参 B 和韩国红参 C)抑制致癌剂苯并(a)芘(B(a)P)诱导的肺癌形成和生长的能力,发现韩国红参 B 在四种红参品种中降低肿瘤负荷的效果最显著。此外,我们分析了四种红参提取物中各种人参皂苷(Rg1、Re、Rc、Rb2、Rb3、Rb1、Rh1、Rd、Rg3、Rh2、F1、Rk1 和 Rg5)的水平,发现韩国红参 B 具有最高水平的人参皂苷 Rg3(G-Rg3),这表明 G-Rg3 可能在其治疗功效中发挥重要作用。这项工作揭示了 G-Rg3 的生物利用度相对较差。然而,当 G-Rg3 与 P-糖蛋白抑制剂维拉帕米联合使用时,Caco-2 细胞中 G-Rg3 的外排作用降低,大鼠模型中 G-Rg3 的小肠吸收率增加,G-Rg3 在肠道和血浆中的浓度水平升高,其在 B(a)P 诱导的肿瘤发生大鼠模型中的肿瘤预防能力也增强。我们还发现,G-Rg3 降低了 B(a)P 诱导的人肺细胞的细胞毒性和 DNA 加合物形成,并通过 Nrf2 通路挽救了 II 相酶的表达和活性,这可能是 G-Rg3 抑制肺癌发生的潜在机制。我们的研究表明,G-Rg3 在靶向小鼠模型中的肺肿瘤方面可能发挥着至关重要的作用。通过靶向 P-糖蛋白,增加了这种人参皂苷的口服生物利用度,使其能够发挥抗癌作用。